CC - Analyst questions/MGT answers Operator
[Operator Instructions]. Our first question comes from Doug Cooper from Beacon Securities.
Doug Cooper
Thanks for the very comprehensive uptick, Greg and Hardik. When I look out into 2023 across your various products, can you give us a sort of outlook by category, say, between oxygen, CPAP and events where you see growth like is one more than the other? Or just a bit more color on the growth of each of the products?
Gregory Crawford
Thanks, Doug. That stayed pretty steady for us in that -- actually, over the past several years in that with that product mix in that, and we would continue to expect that in that to stay on that kind of 80% respiratory side and the other 20% being kind of other invert DME supplies and things like that and other supplies as a total percentage of revenue, although we are starting to look at different product categories that can complement in that those -- and help those other respiratory patients that we do have. But I don't think there'll be any big swing in that as a percentage of revenue in 2023.
Doug Cooper
Okay. Hometown Medical closed, I guess, early July you almost got a full quarter contribution, I guess, from that in the quarter. Is there any -- are all the acquisitions, say, from access to NORCAL, you could maybe -- are all of them fully integrated now? Or do you anticipate any more cost savings along the line?
Gregory Crawford
Yes, that's a very good question in that. I'll say we're winding down in that the complete integration of those and looking out into '23 and that especially with the CPI increases that have came out. And then we also believe that peak inflation that is likely run through the business should we kind of stay the same on that front in that, that there could likely be some pickup in the margin as we complete the full integration of those acquired businesses, especially the ones that were kind of towards that, we'll say, June, July time frame.
Doug Cooper
Okay. And last one for me. Just that you talked about your growth -- the 3-pronged growth strategy, increasing the sales team, to add more to the sales team. Can you quantify that? And are you looking to grow the sales team by 10% kind of thing? Or what -- maybe just give more color on that?
Gregory Crawford
Yes, sure. That's been something that has -- frankly, has been a little bit of a struggle for us just through the pandemic and everything and really the access points in that more than anything, we'll be able to make those call points. But we've consistently seen that open up and that to where they've been able to have face-to-face meetings and presentations in that. So we would expect this year in that to and increase that 50%, and that would kind of be the bar -- the low part of the bar on that. We're well on our way to get that done in that. We've consistently been adding additional reps. It does take some time to get them ramped up and that to where they're really contributing in that 6 month plus or so. So we're pretty excited about '23.
Doug Cooper
Okay. And Hardik, just sort of when can we expect the filings on SEDAR to be done?
Hardik Mehta
Pretty soon. Obviously, the deadline is the 28, but we expect to do it sooner than that.
Doug Cooper
Okay. But not -- won't be out today, you think?
Hardik Mehta
Not today.
Operator
Our next question comes from Rahul Sarugaser from Raymond James.
Rahul Sarugaser
Congrats on the rep growth this year. So I just wanted to check in on the guidance of $180 million top line by the end of calendar year, given that we've seen how much in July, partial contribution. How is the company tracking towards that guidance?
Gregory Crawford
Yes, sure. So that was some guidance that was given on exiting in that our fiscal Q1 '23 number here in that, which is the calendar in that. So I'll say we do have a little, ways to go. We haven't reported those numbers yet, and that will be in February. It's hard for us in that to predict the timing in that of some of these acquisitions in order to kind of give out in that exactly when that's going to happen, but we do have a very high confidence level in being able to meet that outlook.
Rahul Sarugaser
Okay. Great. And if you don't mind if I just drill a little bit further. So in order to meet that outlook, you probably need to be adding about $20 million in [indiscernible] just less than over Q1 towards the end of the calendar year. And so even if we estimate sort of smaller acquisitions, that's around 4-ish. So could you maybe give us a sense, even though timing is a little less unpredictable, how we should be thinking about the number of acquisitions in order to get that -- hit that target and sort of the general sort of size of those acquisitions to hit that target?
Gregory Crawford
Yes. Well, we continue to remain focused on all 3 prongs in that of our acquisition strategy in that. So with the smaller sized companies, say, 5 million are under and then also kind of those key -- turnkey respiratory in that, that would be in that $5 million to $20 million and then also in that continue proving through additional larger acquisitions. So it's really hard to kind of give what's going to make it to the finish line with that timing and that on those particular acquisitions, whether it's 1 or it's 3 and that to kind of get us there.
Rahul Sarugaser
Okay. That's helpful. And then as we look forward into 2023, or calendar 2023, given sort of the rising rate environment, given sort of the compression on multiples more generally out there, how are you seeing pricing of deals in your pipeline? Are they static? Or do you find that there is -- you're able to pick up assets at slightly cheaper prices given the current environment?
Gregory Crawford
Yes. Sorry about the pause of silence in that, I believe, Hardik, in that was answering that question, but having --
Hardik Mehta
Sorry. I'm sorry.
Gregory Crawford
There you go.
Hardik Mehta
Sorry to hold. This is Hardik. My bad, I probably had been mute somewhere. I guess my response was going into 2023, [indiscernible] I believe that some of the reasons that you just explained would contribute into some kind of adjustments mostly in the favor of a buyer. The magnitude of that is kind of skilled GBD. Generally, we are seeing markets having a slightly lower multiples than what it used to be 3, 4, 5 months ago. But again, from the ones that we are actively working on, they are kind of in the pipeline, but the newer ones, we do expect it to be in favor of a buyer, can't speak to the magnitude of it just yet.
Rahul Sarugaser
Okay. That's helpful. Wishing you the best of luck for the next year.
Operator
Our next question comes from Tania Armstrong-Whitworth from Canaccord Genuity.
Tania Armstrong-Whitworth
On the sleep device backlog, I think you mentioned in your prepared remarks that your -- the supply levels are approaching pre-pandemic levels. Are you able to quantify where that backlog sits today?
Gregory Crawford
Yes. As far as the backlog in that, we're not monitoring it quite like we were before in that because it -- the supply chain in that has drastically improved for us really in real time in that as we're in our fiscal Q1 here, and we expect that to continue into '23, if not, even -- some items even become off of allocation and that, that we're able to order in that. So we've just been laser-focused here and that as we've gotten towards calendar year-end in that towards setups rather than looking at what the backlog is.
Tania Armstrong-Whitworth
Understood. Okay. So we could still see that kind of bubble of increased volume as that backlog has been alleviated in fiscal Q1?
Gregory Crawford
We are seeing an increase in the amount of setups in that -- during this quarter due to availability of inventory.
Tania Armstrong-Whitworth
Okay. Excellent. And then next I think I missed this somewhere, but did you disclose organic growth for the quarter?
Hardik Mehta
Yes. Just to make sure I heard this correctly, what's the question, what was the organic growth for the quarter versus Q3?
Tania Armstrong-Whitworth
Yes, correct.
Hardik Mehta
Yes. So frankly, the organic growth was pretty flat from Q3 to Q4 specifically with the addition of hometown, if you factor that in, I think organic growth was pretty flat.
Tania Armstrong-Whitworth
Okay. And then lastly, on the labor side of things, I know you mentioned that you're starting to grow your sales team a little bit. But even when it comes to the other qualified members of your labor base, what have you seen in terms of wage inflation in the last few months?
Gregory Crawford
Yes. We've seen it stay pretty steady in that. And I think a good way to gauge that and that for us is really look at how efficient has the organization became and look at that labor as a percentage of revenue in that, which is stayed in relatively in the same range really that it has. But we're truly -- we are seeing significant increases in salaries. There's no question about that. But at the same time, in that our talent pools got much better. So we've been able to create a lot of efficiencies throughout the organization and that have really kind of helped with the overall labor expense.
Operator
Our next question comes from Christopher Pu from IA Capital Markets.
Christopher Pu
Just calling in for Chelsea. Just a couple of quick ones from me. In regards -- just a follow-up to Tanya's question about the sleep devices. What's the status of any like updates for the sleep device? Is there any like implementation of like new sleep devices once this current backlog eventually clears? I'm just kind of wondering about that.
Hardik Mehta
As Greg mentioned earlier, right, we are seeing some influx of how fresh inventory coming in. We are also getting indications from our suppliers that as we go into Q2 2023 or calendar Q1, some of the restrictions that were in place, even those restriction have reduced over the last couple of quarters, but even whatever the minimum restrictions they still have in place or allocations they have in place, which should be fully lifted by end of calendar Q1. So that said, we really don't -- based on our market intelligence and the communications we are having with our vendors, we believe that by end of Q1, calendar Q1, there shouldn't be any shortage as far as devices are concerned.
Christopher Pu
All right. And my last question is, is your company going to provide like a run rate guidance for calendar year 2023?
Hardik Mehta
No, I think at this point, we would not, but maybe sometimes later in the year and there are a few things in the pipeline that we are not at liberty to discuss at this point. But maybe once we have those all materialized or got to the finish line one way or the other, maybe that would be a good point of time where we would discuss some guidance.
Operator
Our next question comes from Bill Sutherland from the Benchmark Company.
Bill Sutherland
I wanted to just in on organic growth for a minute. I wanted to just see if you could help us understand the trend in 4Q and then a little bit more. And then with the various components that you mentioned that will add to organic growth in the current fiscal year. If you could help frame that in some way, I'm not sure if [indiscernible] want to talk about the kind of level of growth you think is possible with these various factors, but that would be great.
Hardik Mehta
Sure. So maybe I'll refrain from [indiscernible] some of the things, but I'm glad you asked that question because I thought I probably didn't do it justice to my response to Tania's question. If you go back in time and look over the last 4 quarters or last 6 quarters, specifically how the recall took place and the device shortages started affecting, there is a casketing effect of those things, right, from review setups to eventually a tax setting effect of the recurring increase of that business, which is resupplies that you put in place in every 3 months. And I think what you see here in the last Q3, Q4 time frame is us kind of hitting that bottom from that casketing effect.
And I think from what we are looking at in terms of fiscal Q1 '23 and going forward, now we are going into the reversal of that casketing effect where you would now see not only the device setups are increasing, but then as you go into the next few quarters, 3, 4 of 2023 and going into Q1 of 2024 as well, we will start seeing the -- again, the good casketing impact of new setups with increased recurring supply that continues to grow and you see the full impact of that about at least 5 quarters out is when you kind of max it out, right, in terms of recovery you got from the additional setups that we are going to do starting this quarter. So I think that kind of explains why Q3 and include in Q4, the expected organic growth or where not a thing compared to our historical standards. So again, glad for asking that question because I think I should have included that as a response to Tanya's question.
I think going into 2023, certainly, there should be some increased tailwinds as a result of what I just explained. On top of that, there is a CPI increase as well. You guys all can do the math. Medicare has been a decent percentage, almost 40% of our revenue, 35% to 40% of our revenue. And the weighted average, if you look at the CPI increases from 6.4% to down 9%, so somewhere in between is where we would put a weighted average. So we can all factor in what that organic growth would look like just from a CPI increase plus the additional growth from this availability of devices and the recurring nature of those, we do suddenly expect us to, at a minimum, hit our historical growth rate, which was kind of somewhere between 7% to 10% in the past to hit in 2023, again we hope that we actually see that. But at minimum, we would like to at least go back to where we used to be, which is still substantially higher than the market growth rate of about 4% to 5%.
Bill Sutherland
Great. That's great detail. And so -- okay, I suppose you're including the plans on the sales force expansion, [indiscernible] locations, product line expansion. I mean I feel like there's a lot of pieces here that kind of make 7% to 10% very easy bar to get over?
Hardik Mehta
You said 7% to 10% is pretty easy bar?
Bill Sutherland
It feels like. Is that what you said?
Hardik Mehta
Yes, we would feel like that too, frankly speaking, but we obviously don't want to -- if you followed our story, you would obviously try to commit to what we think we can minimally do, but we certainly should further [indiscernible]. We're not obviously forecasting the starts, but I think given the very basis what we think, we can certainly achieve given the tailwinds.
Bill Sutherland
Okay. Great. That's all I have. Thanks, Hardik.
Hardik Mehta
Thanks. Sure.
Operator
This concludes the question-and-answer session. I would like to turn the conference back over to Greg Crawford for any closing remarks.